Celgene Corporation (NASDAQ:CELG) will host a conference call and live audio webcast on Thursday, April 24, 2014 at 9 a.m. ET to discuss first quarter 2014 financial and operational results. Celgene Corporation (NASDAQ:CELG) shares after opening at $142.00 moved to $147.17 on last trade day and at the end of the day closed at $146.60. Company price to sales ratio in past twelve months was calculated as 9.17 and price to cash ratio as 10.47. Celgene Corporation (NASDAQ:CELG) showed a positive weekly performance of 1.45%.
Questcor Pharmaceuticals, Inc. (NASDAQ:QCOR), released that it is contributing $175,000 to the Child Neurology Society and Child Neurology Foundation to further endow the Philip R. Dodge Young Investigator Award. Questcor Pharmaceuticals Inc. (NASDAQ:QCOR) shares advanced 6.99% in last trading session and ended the day on $69.47. QCOR return on equity ratio is recorded as 94.20% and its return on assets is 50.60%. Questcor Pharmaceuticals Inc. (NASDAQ:QCOR) yearly performance is 126.73%.
Investment analysts at Goldman Sachs started coverage on shares of Clovis Oncology (NASDAQ:CLVS) in a note issued to investors on Monday, TheFlyOnTheWall.com reports. The firm set a “neutral” rating on the stock. Clovis Oncology Inc. (NASDAQ:CLVS) shares moved up 2.54% in last trading session and was closed at $71.03, while trading in range of $68.37 – $72.47. Clovis Oncology Inc. (NASDAQ:CLVS) year to date (YTD) performance is 17.85%.
MannKind Corporation (NASDAQ:MNKD) announced that the Endocrinologic and Metabolic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) voted 13 to 1 to recommend that AFREZZA (insulin human [rDNA origin]) Inhalation Powder be granted marketing approval by the FDA to improve glycemic control in adults with type 1 diabetes and voted 14 to 0 to recommend that AFREZZA be granted marketing approval by the FDA to improve glycemic control in adults with type 2 diabetes. MannKind Corporation (NASDAQ:MNKD) weekly performance is -31.98%. On last trading day company shares ended up $4.02. MannKind Corporation (NASDAQ:MNKD) distance from 50-day simple moving average (SMA50) is -28.83%. Analysts mean target price for the company is $7.07.
Leave a Reply